@alliance

Congrats to @Daya_HQ (ALL15) on their $2.4m raise. Daya lets African businesses bank in USD and pay anyone worldwide.

Freeport Markets (@freeportmarkets) gives retail traders buy/sell signals as breaking news happens, allowing users to trade ahead of price moves. With $60M traded and growing 50% month-over-month, it's clear that a new generation of traders is adopting the tools once reserved for Wall Street. Congrats on the launch @Bryan__Reed and @Lihong062. https://t.co/wLY8dw1KmE

We asked @usv's Nikhil (@uninsightful) one question: why NYC? 0:25 How Nikhil joined USV 1:15 Showcasing the USV office 1:54 Lessons learned from @fredwilson 2:50 SF vs NYC from a builders perspective 3:46 USV's investing approach 4:40 NYC's culture & lifestyle 5:42 NY is the place to get customers

This is the story of four proteins that can rewind aging, and the $4 billion racing to put them inside a human being. For a century, biologists treated aging like a rusting car. Parts wear out, damage piles up, no reverse gear. A small group now argues that's wrong. Much of what looks like permanent damage, they say, is really a software problem, and software can be rewritten. Every cell in your body carries identical DNA. What makes one a neuron and another a skin cell is a second layer of information sitting on top, telling each cell which genes to run. The heretical claim is that aging is the slow corruption of that information. And in 2006, a failed orthopedic surgeon named Shinya Yamanaka found four proteins that can retrieve it. His recipe could take a fully specialized cell and walk it all the way back to a blank, become-anything state. It won him a Nobel. Then scientists found something stranger. Turn the factors on briefly, not long enough to erase a cell's identity, and old mice get younger by every measure, and live about 30% longer. A heart cell stays a heart cell. Just younger. The boundary with cancer is razor thin. Run the factors too long and you manufacture tumors in bulk. The whole trick depends on not finishing. Now the money has arrived. Bezos backs @altos_labs. Sam Altman seeded @RetroBio_. Brian Armstrong co-founded @newlimit. David Sinclair's Life Biosciences got through the door first. In January 2026, its eye therapy became the first cellular reprogramming treatment ever cleared for human testing. The realistic prize isn't immortality. Nobody's living to 300 on an eye injection. It's compression of morbidity, squeezing the sick, declining years at the end of life into a shorter window. The question has finally narrowed. Not "can a cell be made young?" but "can a patient be made well?" By the early 2030s, we'll know. Read @QwQiao's essay on the Yamanaka factors below.

NYC always, Knicks in 4. https://t.co/0qOoUp5C5X